Exciva

ActiveOn the Germany Radar · not ranked

Neuropsychiatry

Last roundSeries B · Jan 2026

Why Exciva is not ranked yet

The Radar lists every known eligible company, sorted by date of last round, with no AI judgement. Exciva enters the ranking once its public data is sufficient for the AI to estimate it. Next Germany edition: 11 Oct 2026.

Funding history

Date	Round	Amount	Type	Investors
Jan 2026	Series B	EUR 51M (USD 59M)	—	Gimv, Fountain Healthcare Partners

Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Uback rankings

How the AI ranks →

Ranking	Tier	Rank	Edition	Next update
Germany · all sectors	Radar	—	Edition 0 – beta · October 2026	11 Oct 2026

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Exciva as a PDF, on one of three angles only:

ValuationWhat is Exciva worth?

Versus competitorsHow does it compare?

Who should acquire itStrategic buyers, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication.

Invest

Back Exciva whether or not it has agreed: your intention joins the pool on Exciva, passed to the local partner once it reaches critical mass. Declaring an intention does not mean this company is raising funds.

Back Exciva Or back biotech in Germany

Pool on ExcivaBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until a deal process opens. If the company does not follow up, Uback invites its Backers to move their intentions to a competitor or a similar company. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run Exciva?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round.

Claim this profile Report an upcoming round → Report an error →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Read by the AI at the next edition.

Comparable companies in Germany

Full Germany ranking →

Tubulis#17Biotech › antibody-drug conjugatesUnicorn CatalYm#34Biotech › cancer immunotherapyHundreds of M$SciRhom#50Biotech › antibodies for autoimmune diseaseHundreds of M$Helsing#1Defence › AI software and strike dronesDecacorn

Investors in Exciva: Gimv · Fountain Healthcare Partners

Last updated: Oct 2026Report an error

Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.